Glycopyrrolate bromide: Phase III started

Sumitomo’s Sunovion Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, U.S. Phase III GOLDEN-3 and GOLDEN-4 trials to evaluate 25 and 50 ug SUN-101 twice daily for 12 weeks ea...